Some parts of glioblastoma can be resistant to treatment, while others respond really well.
Arshiya, from our research team, explains how research in Leeds is searching for these differences as they occur during treatment.
Sisters Katy and Rebecca lost their dad to a glioblastoma and want you to help fund the nanobiopsy project.
Glioblastomas are the most common, and one of the most aggressive types of brain cancer found in adults. The standard treatment involves surgery to remove as much of the tumour as possible, followed by radiotherapy and chemotherapy.
However, the tumour always grows back so we need to understand why these treatments are failing.
What we don't know is whether glioblastoma cells are naturally resistant to treatment or whether treatments cause changes within the cells that make them resistant.
This project is using advanced technology called nanobiopsy to extract tiny samples from living cells without killing them.
Over the course of treatment, the team - led by Dr Lucy Stead at University of Leeds - will be able to take samples to see how the tumour changes.
It's not normally possible to see how glioblastoma cells change during treatment without killing them. This technology - developed by Dr Paolo Actis - will be crucial in comparing treated and untreated cells side-by-side and how they each respond over time and the course of a treatment.
This grant is for two years and up to a total of £119k. Work started in later 2018.